Lung Cancer News and Research

Latest Lung Cancer News and Research

OncoGenex first quarter revenue decreases to $1.2 million

OncoGenex Pharmaceuticals, Inc. today announced its first quarter financial results and provided an update on current events and activities.

10 May 2011

USPTO grants patent to Rosetta's human hsa-miR-497 for use in diagnostic tests

Rosetta Genomics today announced that the United States Patent and Trademark Office has issued U.S. Patent No. 7,943,745, which is related to human hsa-miR-497 and its variants and covers the composition of matter.

10 May 2011

When Government usurps responsibility, people are more likely to abdicate

We hear much talk about preventive care, but nobody has defined it. From the content of the discussions, I deduce that what the health bureaucrats actually refer to would be better characterized as “early detection.” Early detection is what occurs when a physician finds a disease in its early stages that might have been prevented by earlier measures. But who can take those measures? Not the physician, only the patient. There is only one person living the patient’s life; it is the patient. I cannot live his life for him.

9 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Researchers analyze gene expression profiles to understand molecular mechanisms behind various diseases

Over the past decades, researchers seeking to understand molecular mechanisms underlying various diseases, notably cancer, have taken advantage of DNA microarrays to interrogate tissues specimen of patients for the expression status of thousands of genes at once.

9 May 2011

Roundup: Fla. lawmakers to vote today on Medicaid changes; Calif. court expands deadline for tobacco suits

With a sponsor calling it the "most significant transformational change" since Florida's Medicaid program started, lawmakers will vote Friday on a long-awaited proposal to shift almost all beneficiaries into managed-care plans.

7 May 2011

First Edition: May 6, 2011

Today's headlines indicate that the GOP may be rethinking its plans to revamp Medicare -- especially as a new round of debt accord talks begin between Vice President Joe Biden and congressional leaders.

6 May 2011

CAMH presents new Microvolt T-wave Alternans testing data at Heart Rhythm Society meeting

Cambridge Heart, Inc. a developer of non-invasive diagnostic tests for cardiac disease, today announced that new data presented at the Heart Rhythm Society's 32nd Annual Scientific Sessions in San Francisco confirm the diagnostic value of Microvolt T-wave Alternans testing in identifying patients at risk of sudden cardiac arrest.

6 May 2011

MMRF, APGD collaborate to develop OSI-906 for relapsed multiple myeloma treatment

The Multiple Myeloma Research Foundation and Astellas Pharma Global Development, Inc. today announced that they have entered into a joint collaboration for the clinical development of OSI-906 in patients with relapsed multiple myeloma.

6 May 2011

CanTeen launches groundbreaking cancer support system

For these young people, a parent’s cancer can cause great disruption to routines and relationships and can contribute to immense feelings of anxiety and isolation. CanTeen offers young people dealing with their parent's cancer a powerful dual support system in the form of an innovative Offspring Support Program (being launched in Melbourne on 11 May and Brisbane on 17 May, with plans to go national) and a practical FREE resource book Now What…? Dealing with your parent’s cancer, which may be the only help they receive during this difficult time.

5 May 2011

CytRx reports $6.3 million net loss for first quarter 2011

CytRx Corporation, a biopharmaceutical company specializing in oncology, today reported financial results for the three months ended March 31, 2011, and provided a business update.

5 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

ZIOPHARM reports net loss of $39.0 million for first quarter 2011

ZIOPHARM Oncology, Inc, an oncology small molecule and synthetic biology drug development company, today reported its financial results for the three months ended March 31, 2011, and provided an update on the Company's activities in the first quarter.

5 May 2011

ChipDX identifies gene expression signature in early-stage breast tumors

ChipDX LLC, a New York-based molecular diagnostics and personalized medicine research company, has discovered a gene expression signature present in the cells of early-stage breast tumors that indicates the chance of the tumor recurring within 10 years.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

Study shows how secondhand smoke may increase vulnerability to nicotine addiction

Exposure to secondhand smoke, such as a person can get by riding in an enclosed car while someone else smokes, has a direct, measurable impact on the brain-and the effect is similar to what happens in the brain of the person doing the smoking.

3 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Bristol-Myers Squibb first quarter net sales increase 5% to $3.3 billion

Bristol-Myers Squibb Company today announced first quarter results that included strong sales and earnings growth, and several key R&D milestones—most notably U.S. regulatory approval for YERVOY. The company also confirmed guidance for the year.

30 Apr 2011

Oncothyreon prices underwritten public offering of common stock

Oncothyreon Inc. today announced that it has priced an underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share for gross proceeds of $40.0 million. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expenses payable by Oncothyreon, will be approximately $37.4 million.

29 Apr 2011